Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mIL12-FHAB
- Development stage
- Preclinical
- Lead developer
- Sonnet BioTherapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
mIL12-FHAB is a preclinical-stage recombinant fusion protein developed by Sonnet BioTherapeutics, consisting of murine interleukin-12 (IL-12) cytokine fused to a proprietary Fully Human Albumin-Binding (FHAB) domain. The FHAB technology utilizes a single-chain antibody fragment (scFv) that binds to serum albumin, allowing the cytokine to "hitch-hike" on albumin for improved pharmacokinetics and targeted delivery to tumor tissues. As the murine surrogate for the clinical candidate SON-1010 (human IL-12-FHAB), mIL12-FHAB is used in preclinical studies to evaluate the efficacy and safety of IL-12-mediated immune activation. It primarily targets the IL-12 receptor to stimulate T-cell and natural killer (NK) cell activity within the tumor microenvironment, promoting anti-tumor immunity.
- Other names
- mouse IL-12-FHABmurine IL-12-FHAB
02
Targets
SPARC (Secreted protein acidic and rich in cysteine)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on mIL12-FHAB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mIL12-FHAB.